Check out this: BioXcel Therapeutics Inc (BTAI) could be on the verge of a big rally

BioXcel Therapeutics Inc (NASDAQ: BTAI) is -28.47% lower on its value in year-to-date trading and has touched a low of $2.23 and a high of $34.12 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BTAI stock was last observed hovering at around $3.75 in the last trading session, with the day’s loss setting it -1.64%.

Currently trading at $2.11, the stock is -31.73% and -33.23% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.02 million and changing -43.73% at the moment leaves the stock -75.14% off its SMA200. BTAI registered -93.65% loss for a year compared to 6-month loss of -71.45%. The firm has a 50-day simple moving average (SMA 50) of $58.90 and a 200-day simple moving average (SMA200) of -$0.37.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

The stock witnessed a -22.71% gain in the last 1 month and extending the period to 3 months gives it a -54.72%, and is -31.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 21.04% over the week and 9.99% over the month.

Profit margin for the company is -17037.44%. Distance from 52-week low is -5.38% and -93.82% from its 52-week high. The company has generated returns on investments over the last 12 months (-358.57%).

BioXcel Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.91 with sales reaching $740k over the same period.The EPS is expected to shrink by -3.65% this year, but quarterly earnings will post 356.00% year-over-year. Quarterly sales are estimated to grow 210.90% in year-over-year returns.

BioXcel Therapeutics Inc (BTAI) Top Institutional Holders

121 institutions hold shares in BioXcel Therapeutics Inc (BTAI), with institutional investors hold 48.15% of the company’s shares. The shares outstanding are 28.15M, and float is at 20.68M with Short Float at 11.88%. Institutions hold 33.81% of the Float.

The top institutional shareholder in the company is FMR, LLC with over 4.37 million shares valued at $29.13 million. The investor’s holdings represent 14.94% of the BTAI Shares outstanding. As of Jun 29, 2023, the second largest holder is State Street Corporation with 2.07 million shares valued at $13.8 million to account for 7.08% of the shares outstanding. The other top investors are Adage Capital Partners GP L.L.C. which holds 1.95 million shares representing 6.67% and valued at over $13.0 million, while Blackrock Inc. holds 4.75% of the shares totaling 1.39 million with a market value of $9.25 million.

BioXcel Therapeutics Inc (BTAI) Insider Activity

A total of 5 insider transactions have happened at BioXcel Therapeutics Inc (BTAI) in the last six months, with sales accounting for 0 and purchases happening 5 times. The most recent transaction is an insider sale by Mehta Vimal ,the company’sCEO and President. SEC filings show that Mehta Vimal sold 30,000 shares of the company’s common stock on Jun 16 at a price of $20.18 per share for a total of $0.61 million. Following the sale, the insider now owns 39903.0 shares.

BioXcel Therapeutics Inc disclosed in a document filed with the SEC on Jun 15 that Mehta Vimal (CEO and President) sold a total of 30,000 shares of the company’s common stock. The trade occurred on Jun 15 and was made at $21.54 per share for $0.65 million. Following the transaction, the insider now directly holds 39903.0 shares of the BTAI stock.

Still, SEC filings show that on May 22, Mehta Vimal (CEO and President) disposed off 6,500 shares at an average price of $25.79 for $0.17 million. The insider now directly holds 37,294 shares of BioXcel Therapeutics Inc (BTAI).